Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (BIVI) is a clinical-stage biotechnology company pioneering novel therapies for chronic liver disease complications and neurodegenerative disorders. This page serves as the definitive source for all official company updates, including clinical trial progress, regulatory milestones, and strategic developments.
Access real-time announcements about BIV201 for liver ascites management and bezisterim for Alzheimer’s/Parkinson’s research. Stay informed on orphan drug designations, partnership agreements, and financial disclosures that shape BioVie’s innovative pipeline.
All content is rigorously curated to provide investors and researchers with compliant, actionable insights. Bookmark this hub for authoritative updates on therapies addressing critical unmet medical needs through advanced clinical research.
BioVie Inc. (NASDAQ: BIVI) announced a pause in patient enrollment for its Phase 2b clinical trial of BIV201, aimed at treating refractory ascites. Initial results from 15 patients showed a 34% reduction in ascites fluid after 28 days of treatment, significantly outperforming those receiving standard care. Notably, patients who completed treatment experienced a 53% reduction in ascites fluid, indicating the potential of BIV201 as a treatment option. The drug has received Orphan Drug and Fast Track designations from the FDA, and the company plans to discuss progressing to a pivotal Phase 3 trial.
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 13-15, 2023. The virtual presentation will take place on March 15, 2023, at 12:40 PM ET, featuring one-on-one investor meetings. BioVie is focused on developing innovative drug therapies for neurological disorders, including Alzheimer's and Parkinson's diseases, and advanced liver disease. Their drug candidate NE3107 is undergoing pivotal trials for Alzheimer's, while BIV201 is in a Phase 2b study for liver cirrhosis. The company aims to improve patient outcomes with its groundbreaking therapies.
BioVie (NASDAQ: BIVI) has announced encouraging preliminary results from its Phase 2 trial of NE3107 for Parkinson's Disease (PD). Six out of 20 patients treated with NE3107 experienced a morning 'on state', compared to none in the placebo group (p=0.02). This state is crucial for PD patients as it indicates optimal motor function. Additionally, NE3107-treated patients showed a significant improvement in motor scores on the Unified Parkinson's Disease Rating Scale compared to those on levodopa alone. The company plans to initiate Phase 3 trials for NE3107, following favorable Phase 2 results.
BioVie Inc. (NASDAQ: BIVI) announced the successful completion of patient enrollment for its NM101 trial, evaluating NE3107 in Alzheimer’s patients, achieving a revised target of 400 patients. The trial is a pivotal Phase 3 study aimed at assessing cognition and function in mild to moderate Alzheimer’s disease patients. Top line results are anticipated in October 2023. The study protocol adapted to increased interest, allowing for enhanced statistical power. Previous Phase 2 results indicated improved cognition with NE3107 treatment. The company aims to address neuroinflammation and insulin resistance related to neurodegenerative diseases.
BioVie (NASDAQ: BIVI) has announced its upcoming BioVie Day on March 23, 2023, at 10 a.m. EST, where it will present a comprehensive overview of recent clinical trial data on its treatments for Alzheimer's, Parkinson's, and liver diseases. This event aims to summarize progress, discuss new clinical trials, and outline plans for regulatory submissions. Notable achievements include the promising Phase 2 results for NE3107 in Alzheimer's and Parkinson's, showing significant cognitive and motor control improvements. Additionally, the liver disease candidate BIV201 holds FDA Fast Track status. More details will be shared as the date approaches.
BioVie Inc. (NASDAQ: BIVI) will be featured in an interview on The RedChip Money Report on Bloomberg TV on December 31, 2022, at 7 p.m. ET. CEO Cuong Do will discuss positive Phase 2 clinical trial data for Alzheimer's and Parkinson's diseases, and plans for potential FDA approval in 2024. BioVie is developing innovative therapies for neurodegenerative disorders and liver disease, with key studies underway for its drug candidates NE3107 and BIV201. The interview will be accessible online and aims to inform investors about the company’s progress.
BioVie Inc. (NASDAQ: BIVI) recently reported significant advancements with its drug candidate NE3107 for treating Parkinson's disease (PD) and Alzheimer's disease (AD). In a trial, PD patients using NE3107 experienced a meaningful increase in motor control after 28 days. Additional data indicated that NE3107 improved cognition in mild cognitive impairment and mild AD patients. Notably, NE3107 reduced biomarkers of aging-related disease by approximately 3.3 years after 3 months of treatment. The company is moving toward Phase 3 trials based on promising results.
BioVie Inc. (NASDAQ: BIVI), a clinical-stage company, announced positive findings from its Phase 2 trial for NE3107, aimed at improving cognitive functions in Alzheimer's patients. The study revealed NE3107 may reduce Horvath DNA methylation SkinBlood clock by 3.3 years after 3 months of treatment. Among 23 patients, results indicated significant cognitive enhancement, with 2.2 point improvement on the modified ADAS-Cog12 scale and a reduction in CSF phospho-tau levels. No adverse events were reported, suggesting NE3107's potential in addressing aging-related diseases.
BioVie Inc. (BIVI) announced positive results from two Phase 2 trials evaluating NE3107 for Parkinson's and Alzheimer's diseases. In the Parkinson's trial, patients receiving NE3107 with levodopa achieved a clinically meaningful improvement of over 3 points in motor function compared to levodopa alone. Notably, those under 70 saw a 6-point enhancement. In the Alzheimer's trial, NE3107 improved cognition, showing a 2.1-point gain on the ADAS-Cog12 scale. Additionally, biomarkers related to neuroinflammation decreased without any adverse effects reported.
BioVie Inc. (BIVI) has increased the enrollment target for its Phase 3 trial evaluating NE3107 in Alzheimer’s patients from 316 to 400 due to rapid recruitment and favorable safety data. Over 316 patients are already enrolled, and the company anticipates completing enrollment in two months, with topline results expected by 3Q2023. The trial aims to assess cognition and functional improvement in patients with mild to moderate Alzheimer's disease. The decision to expand enrollment is based on positive early findings and the absence of serious adverse events.